Efficacy Study of Acupuncture on Spinal Compression Fracture

NCT ID: NCT01913587

Last Updated: 2021-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to investigate the effectiveness of acupuncture for alleviating pain from Spinal Compression Fracture in Patients Treated with Nerve Block.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spinal compression fracture is mainly caused by trauma, furthermore, in old age, osteoporosis increases the risk of spinal compression fracture. Nerve block is effective for the management of pain from inflammation or nerve root stimulation from spinal compression fracture. As one of alternative interventions, acupuncture is effective for controlling spinal compression fracture.

This study aims to investigate that combination with acupuncture and nerve block may relieve spinal compression fracture-related pain versus nerve block alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Compression Fracture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acupuncture & Nerve block

Acupuncture will be performed 3 times per week, total 9 sessions, during 3 weeks. Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.

Group Type EXPERIMENTAL

Acupuncture

Intervention Type DEVICE

Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).

Nerve block

Intervention Type PROCEDURE

Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).

Nerve block

Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.

Group Type ACTIVE_COMPARATOR

Nerve block

Intervention Type PROCEDURE

Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acupuncture

Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).

Intervention Type DEVICE

Nerve block

Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Vertebral compression fracture by trauma or osteoporosis
* Minimum 15% height loss of vertebrae
* Patient diagnosed with x-ray or computed tomography (CT) or magnetic resonance image (MRI)
* Visual analogue scale (VAS) score of 5 or more
* Age over 50
* 2 weeks from onset or more
* Follow-up possible during the clinical trial
* Written informed consent voluntarily

Exclusion Criteria

* Within 2 weeks from onset
* Pathological fracture due to malignancy/myeloma, osteomyelitis
* Major retropulsion of bony segments into the spinal canal
* Bone metabolic disease
* Significant renal or hepatic disease
* Hypersensitive reaction to acupuncture treatment
* Senile dementia, impaired cognitive function or other cerebral disease, severe psychiatric or psychological disorders
* Alcohol/drug abuse
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daegu Catholic University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jin Yong Jung

Department of anesthesiolgy

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeong-Chul Seo, KMD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Comprehensive and Intergrative Medicine Institute

Min-Ah Gwak, KMD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Daegu Oriental Hospital of Daegu Haany University

Seong-Hoon Park, KMD

Role: PRINCIPAL_INVESTIGATOR

Comprehensive and Integrative Medicine Insitute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Daegu Catholic University Medical Center

Daegu, Kyungsangbukdo, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIMI-13-01-21

Identifier Type: -

Identifier Source: org_study_id